The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Changes in the myeloma treatment landscape
Faith Davies, MBBCh, MRCP, MD, FRCPath, NYU Langone Health, New York, NY, shares her insights into the future direction of myeloma treatment and the promising results that have been observed from a variety of studies. Dr Davies first mentions some results from the MASTER trial (NCT03224507), which suggests that patients who achieve a good response rate may be able to stop therapy and be monitored over time. Dr Davies then highlights some other changes in the myeloma treatment field, including the numerous studies investigating different therapeutic approaches for high-risk patients, MRD negativity, and how novel drugs such as monoclonal antibodies and proteasome inhibitors will influence this field. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.
